InMode (NASDAQ:INMD) Posts Earnings Results, Beats Estimates By $0.07 EPS

InMode (NASDAQ:INMD) released its quarterly earnings data on Tuesday. The healthcare company reported $0.46 earnings per share for the quarter, topping analysts’ consensus estimates of $0.39 by $0.07, reports. The firm had revenue of $47.00 million during the quarter, compared to analyst estimates of $42.48 million. InMode had a return on equity of 50.50% and a net margin of 30.33%. The business’s quarterly revenue was up 63.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.22 earnings per share. InMode updated its FY20 guidance to $1.85-1.93 EPS and its FY 2020
Pre-Market guidance to 1.85-1.93 EPS.

Shares of InMode stock opened at $40.69 on Wednesday. The company’s 50 day moving average price is $43.27. InMode has a 12 month low of $13.06 and a 12 month high of $58.76. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.83 and a quick ratio of 7.47.

A number of equities analysts recently commented on INMD shares. Zacks Investment Research lowered InMode from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, January 8th. Canaccord Genuity reissued a “buy” rating and set a $50.00 price target on shares of InMode in a research note on Wednesday. Barclays increased their price target on InMode from $27.00 to $45.00 and gave the company an “overweight” rating in a research note on Wednesday, November 6th. Finally, Robert W. Baird reissued an “outperform” rating and set a $55.00 price target (up from $45.00) on shares of InMode in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $44.60.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radio frequency assisted lipolysis and deep subdermal fractional radio frequency technologies. The company offers minimally-invasive aesthetic medical products for procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments.

See Also: What is Depreciation?

Earnings History for InMode (NASDAQ:INMD)

Receive News & Ratings for InMode Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMode and related companies with's FREE daily email newsletter.


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit